Amedisys Inc’s recently made public that its Chief Accounting Officer Guidroz Allyson unloaded Company’s shares for reported $35904.0 on May 08 ’25. In the deal valued at $96.00 per share,374 shares were sold. As a result of this transaction, Guidroz Allyson now holds 8,114 shares worth roughly $0.77 million.
Then, Guidroz Allyson bought 374 shares, generating $35,853 in total proceeds.
Before that, Guidroz Allyson sold 2,041 shares. Amedisys Inc shares valued at $187,833 were divested by the Chief Accounting Officer at a price of $92.03 per share. As a result of the transaction, Guidroz Allyson now holds 8,761 shares, worth roughly $0.83 million.
Deutsche Bank downgraded its Amedisys Inc [AMED] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including William Blair’s analysts, who decreased its forecast for the stock in early July from “an Outperform” to “a Mkt perform”. Truist also remained covering AMED and has decreased its forecast on June 07, 2023 with a “Hold” recommendation from previously “Buy” rating. Cantor Fitzgerald started covering the stock on April 21, 2023. It rated AMED as “a Neutral”.
Price Performance Review of AMED
On Tuesday, Amedisys Inc [NASDAQ:AMED] saw its stock fall -0.96% to $94.50. Over the last five days, the stock has lost -1.68%. Amedisys Inc shares have risen nearly 4.09% since the year began. Nevertheless, the stocks have fallen -0.05% over the past one year. While a 52-week high of $98.95 was reached on 05/06/25, a 52-week low of $82.15 was recorded on 02/21/25. SMA at 50 days reached $93.11, while 200 days put it at $93.52.
Levels Of Support And Resistance For AMED Stock
The 24-hour chart illustrates a support level at 94.24, which if violated will result in even more drops to 93.99. On the upside, there is a resistance level at 95.01. A further resistance level may holdings at 95.53. The Relative Strength Index (RSI) on the 14-day chart is 53.34, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.44%. Stochastics %K at 52.42% indicates the stock is a holding.
The most recent change occurred on March 13, 2023 when Barclays began covering the stock and recommended ‘”an Equal weight”‘ rating along with a $93 price target.
